Compare GLAD & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLAD | CADL |
|---|---|---|
| Founded | 2001 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 430.6M | 455.8M |
| IPO Year | 2001 | 2021 |
| Metric | GLAD | CADL |
|---|---|---|
| Price | $18.40 | $5.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $22.00 | $17.67 |
| AVG Volume (30 Days) | 138.6K | ★ 1.4M |
| Earning Date | 11-17-2026 | 11-12-2026 |
| Dividend Yield | ★ 9.54% | N/A |
| EPS Growth | ★ 91.82 | 58.62 |
| EPS | ★ 1.00 | N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | $12.97 | N/A |
| Revenue Next Year | $9.43 | N/A |
| P/E Ratio | $18.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.54 | $4.35 |
| 52 Week High | $21.73 | $14.00 |
| Indicator | GLAD | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 37.50 | 27.63 |
| Support Level | $18.35 | $4.62 |
| Resistance Level | $19.74 | $5.51 |
| Average True Range (ATR) | 0.44 | 0.72 |
| MACD | -0.06 | -0.30 |
| Stochastic Oscillator | 0.31 | 4.95 |
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.